Recent clinical progress in Gaucher disease

Current Opinion in Pediatrics

Volumn 17, Issue 4, 2005, Pages 519-524

  Grabowski, Gregory A ^a,b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

Author keywords

Enzyme therapy; Gaucher disease; Variant phenotypes

Indexed keywords

MIGLUSTAT;

ANEMIA; BONE DENSITY; CLINICAL FEATURE; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME THERAPY; FRACTURE; GAUCHER DISEASE; GENOTYPE PHENOTYPE CORRELATION; GROWTH RETARDATION; HEPATOMEGALY; HEPATOSPLENOMEGALY; HUMAN; HYPERSPLENISM; MUTATION; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; THROMBOCYTOPENIA;

CHILD; CHILD, PRESCHOOL; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS; INFANT; INFANT, NEWBORN;

EID: 23344450917     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mop.0000172702.33128.19     Document Type: Review

References (29)

1. Beutler E, Grabowski GA. Gaucher disease. In The Metabolic and Molecular Bases of Inherited Diseases. Edited by Scriver CR, Beaudet AL, Sly WS et al. New York: McGraw-Hill; 2001:3635-3668.
2. Brady RO, Barton NW, Grabowski GA. Molecular neurology of the sphingolipidoses. Arch Neurol 1993; 50:1212-1224.
3. Patterson MC, Higgins JJ, Fedio P, et al. Markers of type 3 neuronopathic Gaucher's disease. Neurology 1991; 41:332-333.
4. Dreborg S, Erikson A, Hagberg B. Gaucher disease-Norrbottnian type 1. General clinical description. Eur J Pediatr 1980; 133:107-118.
5. Patterson MC, Horowitz M, Abel RB, et al. Isolated horizontal supranuclear gaze palsy as a marker for severe systemic involvement in Gaucher's disease. Neurology 1993; 43:1993-1997.
6. Grabowski GA, Hopkin RJ. Enzyme therapy for lysosomal storage disease: principles, practice, and prospects. Annu Rev Genomics Hum Genet 2003; 4:403-436.
7. Sidransky E. Gaucher disease: complexity in a 'simple' disorder. Mol Genet Metab 2004; 83:6-15.
8. Charrow J, Andersson HC, Kaplan P, et al. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 2000; 160:2835-2843.
9. Grabowski GA, Andria G, Baldellou A, et al. Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements. Eur J Pediatr 2004; 163:58-66.
10. Baldellou A, Andria G, Campbell PE, et al. Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring. Eur J Pediatr 2004; 163:67-75.
11. Barton DJ, Ludman MD, Benkov K, et al. Resting energy expenditure in Gaucher's disease type 1: effect of Gaucher's cell burden on energy requirements. Metabolism 1989; 38:1238-1243.
12. Rosenthal DI, Doppelt SH, Mankin HJ, et al. Enzyme replacement therapy for Gaucher disease: Skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics 1995; 96:629-637.
13. Charrow J, Andersson HC, Kaplan P, et al. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J Pediatr 2004; 144:112-120.
14. Elstein D, Hadas-Halpern I, Itzchaki M, et al. Effect of low-dose enzyme replacement therapy on bones in Gaucher disease patients with severe skeletal involvement. Blood Cells Mol Dis 1996; 22:104-111.
15. Grabowski GA, Delussie B. Charrow, J., Weinreb, N.J.: The effect of enzyme therapy on bone crises and bone pain in Gaucher disease type 1. Blood 2004, Abstract
16. Pastures GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004; 41:4-14.
17. Theophilus B, Latham T, Grabowski GA, et al. Gaucher disease: molecular heterogeneity and phenotype-genotype correlations. Am J Hum Genet 1989; 45:212-225.
18. Grabowski GA. Gaucher disease: Gene frequencies and genotype/phenotype correlations. Genet Test 1997; 1:5-12.
19. Beutler E, Nguyen NJ, Henneberger MW, et al. Gaucher disease: gene frequencies in the Ashkenazi Jewish population. Am J Hum Genet 1993; 52:85-88.
20. Amaral O, Lacerda L, Santos R, et al. Type 1 Gaucher disease: molecular, biochemical, and clinical characterization of patients from northern Portugal. Biochem Med Metab Biol 1993; 49:97-107.
21. Tsuji S, Choudary PV, Martin BM, et al. A mutation in the human glucocerebrosidase gene in neuronopathic Gaucher's disease. N Engl J Med 1987; 316:570-575.
22. Tylki-Szymanska A, Millat G, Maire I, et al. Types I and III Gaucher disease in Poland: incidence of the most common mutations and phenotypic manifestations. Eur J Hum Genet 1996; 4:334-337.
23. Prows CA, Sanchez N, Daughterly C, et al. Gaucher disease: Enzyme therapy in the acute neuronopathic variant. Am J Med Genet 1997; 71:16-21.
24. Zimran A, Elstein D. Gaucher disease and the clinical experience with substrate reduction therapy. Philos Trans R Soc Lond B Biol Sci 2003; 358:961-966.
25. Cox T, Lachmann R, Hollak C, et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT918) to decrease substrate biosynthesis. Lancet 2000; 355:1481-1485.
26. Erikson A, Groth CG, Mansson JE, et al. Clinical and biochemical outcome of marrow transplantation for Gaucher disease of the Norrbottnian type. Acta Paediatr Scand 1990; 79:680-685.
27. Hobbs JR, Jones KH, Shaw PJ, et al. Beneficial effect of pre-transplant splenectomy on displacement bone marrow transplantation for Gaucher's syndrome. Lancet 1987; 1:1111-1115.
28. Rappeport JM, Ginns EI. Bone-marrow transplantation in severe Gaucher's disease. N Engl J Med 1984; 311:84-88.
29. Tsai P, Lipton JM, Sahdev I, et al. Allogenic bone marrow transplantation in severe Gaucher disease. Pediatr Res 1992; 31:503-507.